核心条款未谈拢 成都先导放弃收购海纳医药

Core Viewpoint - The acquisition of approximately 65% of Nanjing Haina Pharmaceutical Technology Co., Ltd. by Chengdu Xian Dao has been terminated due to failure to reach consensus on key terms of the transaction [1][3]. Group 1: Acquisition Details - Chengdu Xian Dao signed a share acquisition letter of intent with Haina Pharmaceutical and its controlling shareholder in March 2023, intending to become the controlling shareholder post-acquisition [2][3]. - Despite ongoing negotiations and due diligence, the parties could not agree on the transaction plan, price, counterparties, and performance commitments, leading to the termination of the acquisition [1][3]. - The company stated that the termination of the acquisition would not adversely affect its business operations or financial status [3][5]. Group 2: Strategic Implications - The acquisition aimed to expand Chengdu Xian Dao's business from upstream drug discovery to downstream services, creating a comprehensive CRDMO service system [3][4]. - The company expressed a commitment to continue seeking suitable acquisition opportunities to enhance its capabilities in drug discovery and optimization [6]. Group 3: Financial Performance - In 2024, Chengdu Xian Dao reported revenue of approximately 427 million yuan, a year-on-year increase of 14.99%, and a net profit of 51.36 million yuan, up 26.13% [7]. - For Q1 2025, the company recorded revenue of about 107 million yuan, a slight decline of 0.6%, while net profit increased by 102.9% to approximately 28.28 million yuan [7]. Group 4: Shareholder Activity - During the acquisition process, three shareholders reduced their holdings, with significant amounts sold at varying price ranges [5].